C M T Fourie1, A E Schutte2, W Smith3, A Kruger4, J M van Rooyen3. 1. Hypertension in Africa Research Team (HART), North-West University, Potchefstroom 2520, South Africa. Electronic address: carla.fourie@nwu.ac.za. 2. MRC Research Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom 2520, South Africa. 3. Hypertension in Africa Research Team (HART), North-West University, Potchefstroom 2520, South Africa. 4. AUTHeR (Africa Unit for Transdisciplinary Health Research), Faculty of Health Science, North-West University, Potchefstroom, South Africa.
Abstract
OBJECTIVE: The role the human immunodeficiency virus (HIV) and antiretroviral treatment on endothelial activation, and the subsequent relationship with cardiovascular disease, is not well understood. We investigated endothelial activation, inflammatory and cardiometabolic profiles, and measures of vascular structure and function of 66 antiretroviral treated (ART), 78 never-treated (no-ART) HIV infected and 165 HIV free Africans. METHODS: Blood samples were obtained for biochemical analysis and blood pressure, pulse wave velocity (PWV) and carotid intima-media thickness (IMT) measurements were performed. RESULTS: The HIV infection duration was at least five years and the treatment 2.86±0.13 years. The intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) levels were elevated in the HIV infected groups compared to the controls. The odds of higher adhesion molecule levels were increased when HIV infected (especially in the no-ART group); OR no-ART vs. no-HIV: ICAM 3.92 (2.2-7.0); VCAM 16.2 (7.5-35). ICAM and VCAM associated with HIV status and interleukin-6 (IL-6) in the total group (all p<0.01). In both HIV infected groups VCAM associated inversely with CD4 counts (no-ART: β=-0.28, p=0.01; ART: β=-0.22, p=0.07) and TC (no-ART: β=-0.36, p<0.01; ART: β=-0.27, p=0.03). The ART group had an unfavourable lipid profile compared to the no-ART group. The inflammatory markers (C-reactive protein (CRP) and IL-6), PWV and IMT did not differ between the three groups. CONCLUSION: HIV infected Africans showed endothelial activation when compared to HIV free controls. The endothelial activation was not accompanied by increased inflammation (as measured with CRP and IL-6), arterial stiffness or sub-clinical atherosclerosis.
OBJECTIVE: The role the human immunodeficiency virus (HIV) and antiretroviral treatment on endothelial activation, and the subsequent relationship with cardiovascular disease, is not well understood. We investigated endothelial activation, inflammatory and cardiometabolic profiles, and measures of vascular structure and function of 66 antiretroviral treated (ART), 78 never-treated (no-ART) HIV infected and 165 HIV free Africans. METHODS: Blood samples were obtained for biochemical analysis and blood pressure, pulse wave velocity (PWV) and carotid intima-media thickness (IMT) measurements were performed. RESULTS: The HIV infection duration was at least five years and the treatment 2.86±0.13 years. The intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) levels were elevated in the HIV infected groups compared to the controls. The odds of higher adhesion molecule levels were increased when HIV infected (especially in the no-ART group); OR no-ART vs. no-HIV: ICAM 3.92 (2.2-7.0); VCAM 16.2 (7.5-35). ICAM and VCAM associated with HIV status and interleukin-6 (IL-6) in the total group (all p<0.01). In both HIV infected groups VCAM associated inversely with CD4 counts (no-ART: β=-0.28, p=0.01; ART: β=-0.22, p=0.07) and TC (no-ART: β=-0.36, p<0.01; ART: β=-0.27, p=0.03). The ART group had an unfavourable lipid profile compared to the no-ART group. The inflammatory markers (C-reactive protein (CRP) and IL-6), PWV and IMT did not differ between the three groups. CONCLUSION:HIV infected Africans showed endothelial activation when compared to HIV free controls. The endothelial activation was not accompanied by increased inflammation (as measured with CRP and IL-6), arterial stiffness or sub-clinical atherosclerosis.
Authors: Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman Journal: J Hum Hypertens Date: 2017-03-23 Impact factor: 3.012
Authors: Samson Okello; Stephen B Asiimwe; Michael Kanyesigye; Winnie R Muyindike; Yap Boum; Bosco B Mwebesa; Jessica E Haberer; Yong Huang; Kenneth Williams; Tricia H Burdo; Russell P Tracy; David R Bangsberg; A Rain Mocello; Jeffrey N Martin; Peter W Hunt; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Daniel Muyanja; Conrad Muzoora; Anthony Muyingo; Winnie Muyindike; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2015-12-18 Impact factor: 5.078
Authors: Mark J Siedner; June-Ho Kim; Ruth Sentongo Nakku; Linda Hemphill; Virginia A Triant; Jessica E Haberer; Jeffrey N Martin; Yap Boum; Douglas S Kwon; Alexander C Tsai; Peter W Hunt; Samson Okello; David R Bangsberg Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Mabel Toribio; Magid Awadalla; Madeline Cetlin; Evelynne S Fulda; Takara L Stanley; Zsofia D Drobni; Lidia S Szczepaniak; Michael D Nelson; Michael Jerosch-Herold; Tricia H Burdo; Tomas G Neilan; Markella V Zanni Journal: J Acquir Immune Defic Syndr Date: 2020-10-01 Impact factor: 3.731